Company Management

Synklino

Biotechnology Research 1, 2, Dk 13 employees

Employees: 13
Contacts: 3
Emails: 3
Phones: 1

synklino.com LinkedIn Crunchbase

Synklino Overview

Headquarters: 1, 2, Dk
Phone Number: Available in AeroLeads
Website: synklino.com
Industry: Biotechnology Research
Employees: 13
Founded: 2017
Funding: 32.0M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

About Synklino

Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality. Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.

Synklino Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 1; 25.0% coverage

Synklino Org Chart

Sample employees and titles

Name	Title	Location	Contact
Thomas Kledal	CEO at Synklino	Copenhagen, Capital Region of Denmark, Denmark	Email
John Haurum		Copenhagen, Capital Region of Denmark, Denmark	Email Phone
Jette Wagtberg Sen	Chief Operating Officer at Synklino	Copenhagen Metropolitan Area, Denmark	Email
Mette M Rosenkilde	Professor in Basic and Translational Pharmacology, University of Copenhagen		View